Literature DB >> 26324160

A Comparative Validation of Primary Surgical Versus Post-neo-adjuvant Chemotherapy Sentinel Lymph Node Biopsy for Stage III Breast Cancers.

Gaurav Agarwal1, Sendhil Rajan2, Sanjay Gambhir3, Punita Lal4, Narendra Krishnani5, Subhash Kheruka3.   

Abstract

INTRODUCTION: Sentinel lymph node biopsy (SLNB) is the standard of care for staging N0 primary early breast cancers (EBC). Patients in developing countries mostly present with large (LOBC) or locally advanced cancers (LABC) and are treated with neo-adjuvant chemotherapy (NACT). Accuracy of SLNB in staging stage III N0 and post-NACT N0 patients is uncertain. This prospective validation study on LOBC/LABC patients compared the accuracy of SLNB between primary versus post-NACT surgery.
MATERIALS AND METHODS: Fifty T3/T4, N0 patients undergoing primary surgery (Group I) and 70 LOBC/LABC (index stage) treated with NACT and N0 at the time of surgery (Group II) were inducted. Validation SLNB was performed using low-cost methylene-blue and (99m)Tc-Antimony colloid. SLN identification (IR) and false-negative (FNR) rates were compared between the groups. Sub-group analysis was done in Group II per index tumor and nodal stage to identify factors predicting SLN IR and FNR in post-NACT patients. SLN IR and FNR in both groups were compared with those in previously published SLN validation study and meta-analysis in EBC.
RESULTS: Using combination of blue-dye and radio-colloid, post-NACT SLN IR and FNR (82.9, 13.5 %) were far inferior to T3/T4 primary surgery group (94, 7.7 %; p values 0.034, 0.041) and in EBC. SLN IR using blue-dye alone was dismally low in post-NACT LABCs. Factors predicting unidentified post-NACT SLN and false-negative SLNB included young age, LVI, skin infiltration, extra-nodal spread or N2a stage, and UOQ tumors.
CONCLUSIONS: Accuracy of SLNB in T3, N0 tumors undergoing primary surgery is comparable to that of SLNB for N0 EBC. In post-NACT patients, SLNB IR are lower and FNR are higher. Factors predictive of non-identification and false-negative SLNB include pre-NACT skin involvement (T4b), N2a stage or extra-nodal invasion and LVI, and to a lesser extent, young age and UOQ location of the tumor.

Entities:  

Mesh:

Year:  2016        PMID: 26324160     DOI: 10.1007/s00268-015-3222-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

1.  Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers.

Authors:  S L Wong; C Chao; M J Edwards; T M Tuttle; R D Noyes; D J Carlson; A L Laidley; T Q McGlothin; P B Ley; C M Brown; R L Glaser; R E Pennington; P S Turk; D Simpson; K M McMasters
Journal:  Am Surg       Date:  2001-06       Impact factor: 0.688

2.  Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer.

Authors:  M H Chung; W Ye; A E Giuliano
Journal:  Ann Surg Oncol       Date:  2001-10       Impact factor: 5.344

3.  Sentinel node biopsy for breast cancer larger than 3 cm in diameter.

Authors:  J Schüle; J Frisell; C Ingvar; L Bergkvist
Journal:  Br J Surg       Date:  2007-08       Impact factor: 6.939

Review 4.  Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

Authors:  P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

5.  Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors.

Authors:  I Bedrosian; C Reynolds; R Mick; L S Callans; C S Grant; J H Donohue; D R Farley; R Heller; E Conant; S G Orel; T Lawton; D L Fraker; B J Czerniecki
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

6.  Breast cancer care in developing countries.

Authors:  Gaurav Agarwal; Pooja Ramakant; Ernesto R Sánchez Forgach; Jorge Carrasco Rendón; Juan Manuel Chaparro; Carlos Sánchez Basurto; Marko Margaritoni
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

7.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

8.  The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis.

Authors:  Sarah Pesek; Taka Ashikaga; Lars Erik Krag; David Krag
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

9.  Is breast cancer the same disease in Asian and Western countries?

Authors:  Stanley P L Leong; Zhen-Zhou Shen; Tse-Jia Liu; Gaurav Agarwal; Tomoo Tajima; Nam-Sun Paik; Kerstin Sandelin; Anna Derossis; Hiram Cody; William D Foulkes
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

10.  Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis.

Authors:  Jian-Fei Fu; Hai-Long Chen; Jiao Yang; Cheng-Hao Yi; Shu Zheng
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

View more
  1 in total

1.  Surgical Outcomes of Primary Versus Post-Neoadjuvant Chemotherapy Breast Conservation Surgery: A Comparative Study from a Developing Country.

Authors:  Gaurav Agarwal; Chaitra Sonthineni; Sabaretnam Mayilvaganan; Anjali Mishra; Punita Lal; Vinita Agrawal
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.